Order Article Reprints

Faraoni I, Consalvo MI, Aloisio F, Fabiani E, Giansanti M, Di Cristino F, Falconi G, Tentori L, Di Veroli A, Curzi P, et al. Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. Cancers. 2019; 11(9):1373. https://doi.org/10.3390/cancers11091373

Faraoni, Isabella, Maria Irno Consalvo, Francesca Aloisio, Emiliano Fabiani, Manuela Giansanti, Francesca Di Cristino, Giulia Falconi, Lucio Tentori, Ambra Di Veroli, Paola Curzi, and et al. 2019. "Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes" Cancers 11, no. 9: 1373. https://doi.org/10.3390/cancers11091373

Faraoni, I., Consalvo, M. I., Aloisio, F., Fabiani, E., Giansanti, M., Di Cristino, F., Falconi, G., Tentori, L., Di Veroli, A., Curzi, P., Maurillo, L., Niscola, P., Lo-Coco, F., Graziani, G., & Voso, M. T. (2019). Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. Cancers, 11(9), 1373. https://doi.org/10.3390/cancers11091373